<DOC>
	<DOCNO>NCT01934465</DOCNO>
	<brief_summary>Investigators propose ass , retrospectively prospectively safety tolerability profile ( number participant adverse event ) standard chemotherapy anti-angiogenic agent bevacizumab ( Avastin ) first line treatment patient advance metastatic Non Small Cell Lung Cancer . All treatment schedule go assess consider international guideline standard therapy patient advance metastatic Non Small Cell Lung Cancer .</brief_summary>
	<brief_title>Bevacizumab Plus Chemotherapy Advanced Non Small Cell Lung Cancer Patients 1st Line Treatment</brief_title>
	<detailed_description>In addition investigator propose assess compliance patient treatment efficacy treatment . That mean percentage objective response , duration response , progression free survival estimation overall survival</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>Signed informed consent prior initiation trialspecific procedure treatment Ability comply protocol Histologically cytologically ( sample obtain biopsy bronchoscopy ) confirm nonsquamous NSCLC ( locally recurrent metastatic ) per investigator assessment At least 1 unidimensionally measurable lesion meeting RECIST criterion No prior first line treatment metastatic colorectal cancer Age ≥18 year ECOG performance status ≤2 Adequate haematological , renal hepatic function Urine protein &lt; 2+ ( dipstick ) International normalize ratio ( INR ) ≤ 1.5 activate partial thromboplastin time ( aPTT ) ≤ 1.5 x ULN within 7 day prior randomization , unless prophylactic use anticoagulation Patients asymptomatic treat brain metastasis eligible trial participation . Patients must complete treatment brain metastasis ( radiotherapy without surgery , stereotactic radiosurgery ) , include steroid , least 28 day prior randomization . Treatment anticonvulsant time randomization ( i.e . ≥ 28 day ) allow long anticonvulsant stable dose ) Female patient must pregnant breastfeeding . Female patient childbearing potential ( define &gt; 2 year last menstruation surgically sterile ) must use highly effective contraceptive method ( allow method birth control , i.e . failure rate le 1 % per year , implant , injectables , combine oral contraceptive , intrauterine device [ IUD ; hormonspirals ] , sexual abstinence vasectomize partner ) trial period least 6 month follow last administration trial drug ( ) .Female patient intact uterus ( unless amenorrhoeic last 24 month ) must negative serum pregnancy test within 7 day prior randomization trial Fertile male patient must agree use highly effective contraceptive method ( allow method birth control , i.e . failure rate le 1 % per year , include female partner use implant , injectables , combine oral contraceptive , IUDs [ hormonspirals ] , sexual abstinence prior vasectomy ) trial period least 6 month follow last administration trial drug ( ) Mixed , nonsmall cell small cell tumor mix adenosquamous carcinoma predominant squamous component History hemoptysis ≥ grade 2 ( define bright red blood least 2.5 mL ) within 3 month prior randomization Surgery ( include open biopsy ) , significant traumatic injury within 28 day prior randomization , anticipation need major surgery trial treatment Minor surgery , include insertion indwelling catheter , within 24 hour prior first bevacizumab infusion Evidence tumor invade abut major blood vessel ( e.g. , pulmonary artery superior vena cava ) image Radiotherapy site reason within 28 day prior randomization . Palliative radiotherapy bone lesion within 14 day prior randomization allow Current recent ( within 10 day prior first dose bevacizumab ) use aspirin ( &gt; 325 mg/day ) , clopidogrel ( &gt; 75 mg/day ) , current recent ( within 10 day prior first dose bevacizumab ) use fulldose ( i.e . therapeutic dose ) oral parenteral anticoagulant thrombolytic agent therapeutic purpose . Prophylactic use anticoagulant allow . History evidence inherit bleed diathesis coagulopathy risk bleed Active gastrointestinal bleeding Inadequately control hypertension ( blood pressure : systolic &gt; 150 mmHg and/or diastolic &gt; 100 mmHg ) within 28 day prior randomization history hypertensive crisis hypertensive encephalopathy Clinically significant ( i.e . active ) cardiovascular disease ( e.g . cerebrovascular accident [ CVA ] myocardial infarction within 6 month prior randomization , unstable angina , congestive heart failure [ CHF ] New York Heart Association [ NYHA ] Class ≥ II , serious cardiac arrhythmia ) , uncontrolled medication may interfere administration trial treatment Nonhealing wound , active peptic ulcer untreated bone fracture History abdominal fistula , gastrointestinal perforation intra abdominal abscess within 6 month prior randomization . Treatment investigational agent within 28 day prior randomization . Patients followup phase 1stline trial fulfill eligibility criterion may enrol trial 1stline protocol allows bevacizumabbased treatment followup phase Known hypersensitivity bevacizumab excipients , SOC agent foreseen Malignancy NSCLC within 5 year prior randomization , except adequately treat carcinoma situ cervix , basal squamous cell skin cancer , localize prostate cancer treat curative intent , ductal carcinoma situ ( DCIS ) treat surgically curative intent Evidence disease , neurologic metabolic dysfunction , physical examination find laboratory find give reasonable suspicion disease condition contraindicate use investigational SOC drug use study put patient high risk treatmentrelated complication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Anti-angiogenic agent</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>1st Line</keyword>
</DOC>